naa a22 4500 510763154 CHVBK 20180411083146.0 cr unu---uuuuu 180411e20130101xx s 000 0 eng 10.1007/s12094-012-0891-2 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0891-2 CD44+/CD24− breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties [Elektronische Daten] [Hongmei Sun, Jun Jia, Xiaoli Wang, Bo Ma, Lijun Di, Guohong Song, Jun Ren] Background: Recent studies suggest that the relationship between cancer stem cells (CSCs) and the vascular niche may be bidirectional; the niche can support the growth and renewal of CSCs, and CSCs may contribute to the maintenance of the niche. There is little knowledge concerning the role of breast cancer stem cells in promoting tumor angiogenesis. Aim: For human breast cancers, CSCs have been shown to be associated with a CD44+/CD24 − phenotype. We investigated the potential activities of CD44+/CD24 − breast cancer stem cells in promoting tumor angiogenesis. Methods: The expression of pro-angiogenic genes was determined by quantitative real-time RT-PCR. Endothelial cell migration assays were employed to evaluate effects of conditioned media from CD44+/CD24 − on human umbilical vein endothelial cells. A chorioallantoic membrane (CAM) assay was used to study the potential of CD44+/CD24 − cells to promote angiogenesis. Results: In our study, CD44+/CD24 − cells expressed elevated levels of pro-angiogenic factors compared with CD44+/CD24+ cells. CD44+/CD24 − cell-conditioned media significantly increased endothelial cell migration. Breast cancer cell lines enriched with CD44+/CD24 − cells were more pro-angiogenic in the CAM assay than those lacking a CD44+/CD24 − subpopulation. CD44+/CD24 − cells sorted from MCF-7 cell lines were more pro-angiogenic in a CAM assay than CD44+/CD24+ cells. Furthermore, the VEGF concentration was significantly higher in CD44+/CD24 − cell-conditioned media than in CD44+/CD24+ cell-conditioned media. The pro-angiogenic effect of CD44+/CD24 − cells on endothelial cells was abolished by bevacizumab. Conclusion: Our findings demonstrate that CD44+/CD24 − breast cancer stem cells have substantial pro-angiogenic potential and activity. This provides new insights to explore in the development of targeted therapies. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Breast cancer nationallicence Stem cells nationallicence Angiogenesis nationallicence CSCs : Cancer stem cells nationallicence HUVECs : Human umbilical vein endothelial cells nationallicence FCS : Fetal calf serum nationallicence PBS : Phosphate-buffered saline nationallicence CAM : Chorioallantoic membrane nationallicence Sun Hongmei Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut Jia Jun Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut Wang Xiaoli Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut Ma Bo Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut Di Lijun Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut Song Guohong Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut Ren Jun Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 46-54 1699-048X 15:1<46 2013 15 12094 https://doi.org/10.1007/s12094-012-0891-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0891-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sun Hongmei Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Jia Jun Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Wang Xiaoli Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Ma Bo Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Di Lijun Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Song Guohong Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 700 1- Ren Jun Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, Peking University Cancer Hospital, 52 Fucheng Rd, 100142, Beijing, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/1(2013-01-01), 46-54 1699-048X 15:1<46 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer